Over 35 years of experience and responsibility in all phases of the development of innovative drugs:
at the companies Schering AG (Head of Clinical Development HK & CNS), Grünenthal GmbH (Head of Clinical Development, Chief Medical Officer), Glenmark Pharmaceuticals (Head of Clinical R&D & CMO) and in Consulting (4 years)
​
for NCEs & NBEs in a wide range of indications (including CNS with a focus on neurodegeneration, pain, cardiovascular, pulmonary, autoimmune diseases) and with a focus on rare diseases,
​
in preclinical research, pharmacogenomics, biomarker development and translational medicine,
​
from phase I to phase III, in phase IIIb and IV & non-interventional studies,
​
in the preparation of (successful) approval dossiers (also as a clinical expert), benefit assessments (HTAs) and the preparation and implementation of market launches,
​
in due diligence processes and the critical "deep dive" evaluation of portfolios.